Septerna, Inc. Operating Expenses
Septerna, Inc. (SEPN) reported Operating Expenses of $43.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- Septerna, Inc. operating expenses for the quarter ending 2026-06-30 was $43.58M, a 49.78% increase year-over-year.
- Septerna, Inc. operating expenses for the quarter ending 2026-03-31 was $39.82M, a 52.41% increase year-over-year.
- Septerna, Inc. operating expenses for the quarter ending 2025-12-31 was $40.14M, a 61.01% increase year-over-year.
- Septerna, Inc. operating expenses for the quarter ending 2025-09-30 was $18.88M, a 16.92% decline year-over-year.
- Septerna, Inc. operating expenses for fiscal 2025 was $114.25M, a 39.50% increase from fiscal 2024.
- Septerna, Inc. operating expenses for fiscal 2024 was $81.90M.
- Septerna, Inc. operating expenses for fiscal 2023 was -$1.92M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.58M 10-Q · filed 2026-08-10 | $83.41M 10-Q · filed 2026-08-10 | $123.55M derived: sum of 3 quarters · filed 2026-08-10 | $142.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $39.82M 10-Q · filed 2026-05-11 | $79.96M derived: sum of 2 quarters · filed 2026-05-11 | $98.84M derived: sum of 3 quarters · filed 2026-05-11 | $127.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $40.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $59.02M derived: sum of 2 quarters · filed 2026-03-09 | $88.12M derived: sum of 3 quarters · filed 2026-08-10 | $114.25M 10-K · filed 2026-03-09 |
| 2025-09-30 | $18.88M 10-Q · filed 2025-11-10 | $47.98M derived: sum of 2 quarters · filed 2026-08-10 | $74.11M 10-Q · filed 2025-11-10 | $99.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $29.10M 10-Q · filed 2026-08-10 | $55.23M 10-Q · filed 2026-08-10 | $80.16M derived: sum of 3 quarters · filed 2026-08-10 | $102.88M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $26.13M 10-Q · filed 2026-05-11 | $51.06M derived: sum of 2 quarters · filed 2026-05-11 | $73.78M derived: sum of 3 quarters · filed 2026-05-11 | $92.22M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $24.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $47.66M derived: sum of 2 quarters · filed 2026-03-09 | $66.09M derived: sum of 3 quarters · filed 2026-03-09 | $81.90M 10-K · filed 2026-03-09 |
| 2024-09-30 | $22.73M 10-Q · filed 2025-11-10 | $41.16M derived: sum of 2 quarters · filed 2025-11-10 | $56.97M 10-Q · filed 2025-11-10 | $22.77M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $18.43M 10-Q · filed 2025-08-11 | $34.24M 10-Q · filed 2025-08-11 | $43.00K derived: sum of 3 quarters · filed 2025-08-11 | $12.12M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $15.81M 10-Q · filed 2025-05-15 | -$18.39M derived: sum of 2 quarters · filed 2025-05-15 | -$6.32M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$34.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$22.13M derived: sum of 2 quarters · filed 2025-03-27 | -$1.92M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $12.07M 10-Q · filed 2024-11-20 | $32.27M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |